EUVIMEDEUVIMED entdecken
Leserbrief

Monitoring Anti‐ MDA5 Antibody Titers Associated With Higher GC ‐Free Maintenance in Patients With Anti‐ MDA5 Positive RP ‐ ILD

Yoshiyuki Abe iD, Motoki Takeuchi, Takumi Saito, Masahiro Kogami iD, Naoto Tamura

International Journal of Rheumatic Diseases · 2026-04 · 29 (4)

DOI: 10.1111/1756-185x.70624 ↗

Kurz gefasst

Leserbrief in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 29.03.2026. Verfasst von Yoshiyuki Abe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Rheumatology, School of Medicine, Juntendo University, Tokyo, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Figure S1: Overall survival in patients with anti-MDA5 antibody-positive RP-ILD. (A) Kaplan–Meier curve showing overall survival for the entire cohort, including the early dropout group (n = 48). (B) Kaplan–Meier survival between the pre-antibody monitoring cohort (n = 13) and the antibody monitoring cohort (n = 23), excluding early dropout cases. MDA5, melanoma differentiation-associated gene 5; RP-ILD, rapidly progressive interstitial lung disease. Figure S2: Longitudinal changes in anti-MDA5 antibody titers. (A) Overall trajectories of anti-MDA5 antibody titers during the entire observation period in both groups. (B) Zoomed-in view limited to patients with titers < 100 to visualize low-titer kinetics. (C) Enlarged view of the first 12 months to illustrate early-phase dynamics. (D) Box-and-whisker plots comparing anti-MDA5 antibody levels between the pre-monitoring and antibody monitoring cohorts at selected time points. In both cohorts, titers declined rapidly after treatment initiation, and no statistically significant between-group differences were observed at comparable time points. MDA5, melanoma differentiation-associated gene 5. Figure S3: Kaplan–Meier analysis of time to GC discontinuation after exclusion of patients receiving JAK inhibitors. Sensitivity analysis excluding patients receiving JAK inhibitors. Kaplan–Meier curves for time to GC discontinuation, with patients treated with JAK inhibitors excluded from the analysis. GC, glucocorticoid; JAK, Janus kinase. Table S1: The comparison of characteristics, background, treatment, and prognosis between two groups. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Schlagwörter

Stichwörter der Autor:innen

ELISAGC‐free maintenanceanti‐MDA5 antibodyclinically amyopathic dermatomyositisinterstitial lung disease

Autor:innen und Institutionen

  • Department of Internal Medicine and Rheumatology, School of Medicine, Juntendo University, Tokyo, Japan.

ORCID-Profile: Yoshiyuki Abe, Masahiro Kogami

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Abe, Y., Takeuchi, M., Saito, T., Kogami, M., & Tamura, N. (2026). Monitoring Anti‐ MDA5 Antibody Titers Associated With Higher GC ‐Free Maintenance in Patients With Anti‐ MDA5 Positive RP ‐ ILD. International Journal of Rheumatic Diseases, 29(4). https://doi.org/10.1111/1756-185x.70624

Vancouver

Abe Y, Takeuchi M, Saito T, Kogami M, Tamura N. Monitoring Anti‐ MDA5 Antibody Titers Associated With Higher GC ‐Free Maintenance in Patients With Anti‐ MDA5 Positive RP ‐ ILD. International Journal of Rheumatic Diseases. 2026;29(4). doi:10.1111/1756-185x.70624

BibTeX
@article{Abe2026,
  author = {Abe, Yoshiyuki and Takeuchi, Motoki and Saito, Takumi and Kogami, Masahiro and Tamura, Naoto},
  title = {Monitoring Anti‐ MDA5 Antibody Titers Associated With Higher GC ‐Free Maintenance in Patients With Anti‐ MDA5 Positive RP ‐ ILD},
  journal = {International Journal of Rheumatic Diseases},
  year = {2026},
  volume = {29},
  number = {4},
  doi = {10.1111/1756-185x.70624}
}
Kostenlos starten →